NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Forecast, Price & News $9.90 -0.15 (-1.49%) (As of 05/26/2023 08:46 PM ET) Add Compare Share Share Today's Range$9.84▼$10.2150-Day Range$6.84▼$10.5452-Week Range$4.82▼$10.95Volume76,500 shsAverage Volume98,633 shsMarket Capitalization$474.90 millionP/E RatioN/ADividend YieldN/APrice Target$16.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Alpine Immune Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside65.7% Upside$16.40 Price TargetShort InterestBearish2.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.43) to ($1.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.61 out of 5 starsMedical Sector892nd out of 1,010 stocksPharmaceutical Preparations Industry446th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingAlpine Immune Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.40, Alpine Immune Sciences has a forecasted upside of 65.7% from its current price of $9.90.Amount of Analyst CoverageAlpine Immune Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.40% of the outstanding shares of Alpine Immune Sciences have been sold short.Short Interest Ratio / Days to CoverAlpine Immune Sciences has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Alpine Immune Sciences has recently increased by 8.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpine Immune Sciences does not currently pay a dividend.Dividend GrowthAlpine Immune Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALPN. Previous Next 1.4 News and Social Media Coverage News SentimentAlpine Immune Sciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alpine Immune Sciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ALPN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpine Immune Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders54.70% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.43) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpine Immune Sciences is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpine Immune Sciences is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpine Immune Sciences has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alpine Immune Sciences (NASDAQ:ALPN) StockAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.Read More Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPN Stock News HeadlinesMay 29, 2023 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Growth in Short InterestMay 19, 2023 | finance.yahoo.comAlpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific CongressesMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 13, 2023 | msn.comAlpine Immune Sciences GAAP EPS of -$0.28 beats by $0.09, revenue of $9.4M beats by $2.52MMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Alpine Immune Sciences (ALPN) Buy RecommendationMay 11, 2023 | msn.comRecap: Alpine Immune Sciences Q1 EarningsMay 11, 2023 | finance.yahoo.comAlpine Immune Sciences Reports First Quarter 2023 Financial ResultsMay 9, 2023 | americanbankingnews.comAlpine Immune Sciences (ALPN) to Release Earnings on WednesdayMay 29, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 9, 2023 | americanbankingnews.comAlpine Immune Sciences (ALPN) Scheduled to Post Earnings on WednesdayMay 5, 2023 | finance.yahoo.comPinning Down Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) P/S Is Difficult Right NowMay 1, 2023 | finance.yahoo.comAlpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare ConferenceApril 21, 2023 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest UpdateMarch 29, 2023 | seekingalpha.comAlpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before ProofMarch 29, 2023 | americanbankingnews.comWedbush Comments on Alpine Immune Sciences, Inc.'s Q1 2024 Earnings (NASDAQ:ALPN)March 29, 2023 | americanbankingnews.comSVB Leerink Comments on Alpine Immune Sciences, Inc.'s Q2 2023 Earnings (NASDAQ:ALPN)March 28, 2023 | americanbankingnews.comAlpine Immune Sciences, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.41) Per Share (NASDAQ:ALPN)March 28, 2023 | americanbankingnews.comAlpine Immune Sciences, Inc. to Post Q2 2023 Earnings of ($0.35) Per Share, HC Wainwright Forecasts (NASDAQ:ALPN)March 28, 2023 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Receives Outperform Rating from WedbushMarch 27, 2023 | finance.yahoo.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call TranscriptMarch 27, 2023 | finance.yahoo.comEven though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 yearsMarch 25, 2023 | benzinga.comAlpine Immune Sciences Stock (NASDAQ:ALPN), DividendsMarch 25, 2023 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Price Target Raised to $11.00 at HC WainwrightMarch 24, 2023 | msn.comAlpine Immune Sciences's Return On Capital Employed InsightsMarch 24, 2023 | finance.yahoo.comQ4 2022 Alpine Immune Sciences Inc Earnings CallMarch 24, 2023 | americanbankingnews.comHC Wainwright Increases Alpine Immune Sciences (NASDAQ:ALPN) Price Target to $11.00March 23, 2023 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPN Company Calendar Last Earnings3/23/2023Today5/29/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees85Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.40 High Stock Price Forecast$25.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+65.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,760,000.00 Net Margins-245.92% Pretax Margin-236.91% Return on Equity-40.29% Return on Assets-24.05% Debt Debt-to-Equity RatioN/A Current Ratio3.48 Quick Ratio3.48 Sales & Book Value Annual Sales$30.06 million Price / Sales15.80 Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book2.80Miscellaneous Outstanding Shares47,970,000Free Float21,729,000Market Cap$474.90 million OptionableNot Optionable Beta1.26 Key ExecutivesMitchell H. GoldExecutive Chairman & Chief Executive OfficerStanford L. PengPresident & Head-Research & DevelopmentThaedra ThullberryFinance DirectorJames Paul RickeyChief Financial Officer, Secretary & Senior VPWayne R. GombotzChief Technology OfficerKey CompetitorsProcaps GroupNASDAQ:PROCAnaptysBioNASDAQ:ANABIGM BiosciencesNASDAQ:IGMSNurix TherapeuticsNASDAQ:NRIXBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Bought 33,919 shares on 5/18/2023Ownership: 0.100%Great Point Partners LLCBought 103,043 shares on 5/16/2023Ownership: 7.799%Geode Capital Management LLCBought 70,457 shares on 5/16/2023Ownership: 1.160%State Street CorpBought 43,253 shares on 5/16/2023Ownership: 0.723%Susquehanna International Group LLPSold 11,528 shares on 5/16/2023Ownership: 0.022%View All Institutional Transactions ALPN Stock - Frequently Asked Questions Should I buy or sell Alpine Immune Sciences stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares. View ALPN analyst ratings or view top-rated stocks. What is Alpine Immune Sciences' stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for Alpine Immune Sciences' stock. Their ALPN share price forecasts range from $11.00 to $25.00. On average, they predict the company's stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts. How have ALPN shares performed in 2023? Alpine Immune Sciences' stock was trading at $7.35 at the beginning of 2023. Since then, ALPN stock has increased by 34.7% and is now trading at $9.90. View the best growth stocks for 2023 here. Are investors shorting Alpine Immune Sciences? Alpine Immune Sciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,150,000 shares, an increase of 8.5% from the April 30th total of 1,060,000 shares. Based on an average daily volume of 107,200 shares, the short-interest ratio is presently 10.7 days. View Alpine Immune Sciences' Short Interest. When is Alpine Immune Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ALPN earnings forecast. How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.14. The biotechnology company had revenue of $2.78 million for the quarter, compared to analyst estimates of $10.42 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 40.29% and a negative net margin of 245.92%. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN). What is Alpine Immune Sciences' stock symbol? Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN." Who are Alpine Immune Sciences' major shareholders? Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (7.80%), BlackRock Inc. (3.24%), BVF Inc. IL (1.79%), Geode Capital Management LLC (1.16%), State Street Corp (0.72%) and Renaissance Technologies LLC (0.69%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway. View institutional ownership trends. How do I buy shares of Alpine Immune Sciences? Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alpine Immune Sciences' stock price today? One share of ALPN stock can currently be purchased for approximately $9.90. How much money does Alpine Immune Sciences make? Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $474.90 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How can I contact Alpine Immune Sciences? Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399. This page (NASDAQ:ALPN) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.